These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [10 years of interferon treatment in multiple sclerosis. Does the future belong to high-dose therapy?]. MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579501 [No Abstract] [Full Text] [Related]
23. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo]. Tedeholm H; Skoog B; Hillert J; Runmarker B; Stawiarz L; Oluf A Lakartidningen; 2007 May 30-Jun 3; 104(22):1684-8. PubMed ID: 17601317 [No Abstract] [Full Text] [Related]
24. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. Kalincik T; Horakova D; Dolezal O; Krasensky J; Vaneckova M; Seidl Z; Havrdova E Clin Neurol Neurosurg; 2012 Sep; 114(7):940-6. PubMed ID: 22402204 [TBL] [Abstract][Full Text] [Related]
35. Is it time to consider rationalizing IFN-beta treatment in individuals with multiple sclerosis? Giovannoni G J Neurol Neurosurg Psychiatry; 2004 Sep; 75(9):1234. PubMed ID: 15314107 [No Abstract] [Full Text] [Related]